Executive Vice President;
Chief, External Innovation and Medical Officer
Johnson & Johnson (retired)
Princeton, New Jersey
For extensive contributions to cancer pharmacology, drug discovery, and precision medicine, including early recognition of adverse signal transduction events capable of driving malignant cell growth and advancements in the development of targeted therapies. His research on cyclic nucleotide phosphodiesterase, EF-2 kinase, and multidrug resistance mechanisms laid the foundation for transformative cancer treatments. As a quintessential leader in both academia and industry, Dr. Hait developed New Jersey’s first and only NCI-designated Comprehensive Cancer Center, Rutger’s Cancer Institute, and spearheaded the development of oncology drugs that have improved outcomes for millions of cancer patients. His leadership and dedication to cancer research have profoundly shaped the field, inspiring countless generations of scientists, and have propelled significant innovation in the design and development of novel cancer treatments.
The AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research was established in 2007 to recognize a champion of cancer research whose leadership and extraordinary achievements in cancer research have had a major impact on the field. Such achievements may include scientific contributions to the acceleration of progress against cancer, significant accomplishments associated with national or international awareness of the importance of cancer research, or other ways of demonstrating a sustained extraordinary commitment to cancer research. To learn more please visit the press release.
View Dr. Hait’s Fellow of AACR Academy page.
View Past Recipients.